📰 Atripla Tablets News
Atripla Tablets News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Atripla Tablets. Real-time updates on events, politics, business and more.
October 5, 2023
The company has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the United States Food & Drug Administration (USFDA).
October 4, 2023
The companys product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.
October 4, 2023
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences Atripla tablets which are indicated to help control HIV infection. Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of